secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-06-03T12:30:20+00:00
Accession:  0001193125-26-254658
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology furnishes investor presentation with Phase 2 CRDF-004 interim results
--------------------------------------------------------------------------------

- Presentation covers interim data from randomized Phase 2 CRDF-004 trial of onvansertib + SoC in first-line RAS-mutated mCRC.
- Presentation also details registrational study plans for onvansertib in this indication.
- No specific efficacy or safety endpoints were disclosed in the filing itself; details are in furnished Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526254658/0001193125-26-254658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526254658/crdf-20260603.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-254658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer